Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Pain 1Neoplasms 1Chronic Pain 1

Interventions

Cisplatin 9pembrolizumab 7Radiosurgery 6Gemcitabine 6Paclitaxel 5Dexamethasone 5Taxes 4Carboplatin 4trametinib 3ibrutinib 3Surveys and Questionnaires 3Standard of Care 3Radiotherapy 3Nivolumab 3Magnetic Resonance Spectroscopy 3Lenalidomide 3Fluorouracil 3Erlotinib Hydrochloride 3Blood Specimen Collection 3Ascorbic Acid 3venetoclax 2veliparib 2tocilizumab 2pazopanib 2obinutuzumab 2naquotinib 2lenvatinib 2fludarabine 2enzalutamide 2Vemurafenib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Neoplasms × Sufentanil × Clear all
NCT00943566 2015-09-15

A Safety and Efficacy Study of Sufentanil Transdermal System in Patients With Chronic Pain Due to Cancer

Labtec GmbH

Phase 2 Withdrawn

Neoplasms, Pain, Chronic Pain

Data powered by HemOnc (CC BY 4.0) Colophon âš¡